Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TAVR: If Not Transfemoral, We Should Consider Transcaval Access

Transcatheter aortic valve replacement (TAVR) through transfemoral access has already proven its great benefits, but this access cannot be used in certain patients, and alternative accesses need to be considered for such cases.

Los dispositivos Amplatzer y Figulla demuestran ser seguros para el cierre percutáneo del foramen oval permeable

One of the most commonly used accesses is the transaxillary or transubclavian access (AX), which, however, is associated with more complications (especially stroke). Another alternative—one that is scarcely used—is the transcaval access (TC), although very little information is available in relation to it.

While much less frequently, carotid, apical and transaortic accesses have been used; at present, they are practically not used anymore.

The analysis included 7476 TAVR procedures performed in 8 high-volume sites. Of these, 7132 (95.4%) were performed by transfemoral access (FA), 238 (3.2%) by TC, and 106 (1.4%) by AX.

The primary endpoint was a composite of bleeding and stroke.

The mean age was 77 years. There were more men in the FA and AX groups, but more women in the TC group.

The surgical risk was higher for those in the AX and TC groups.

Read also: Transcaval Access Is Safe in TAVR.

TC access required more contrast and fluoroscopy time.

The primary endpoint was more frequent in non-transfemoral accesses.

The presence of stroke or transient ischemic attack (TIA) was 5 times less frequent in TC than in AX (2.5% vs. 13.2%; odds ratio [OR]: 0.20; 95% confidence interval [CI]: 0.06-0.72; p = 0.014) compared with that for FA, which was 1.7%.

Major bleeding rates were similar between TC and AX accesses (10.0% vs. 13.2%; OR: 0.66; 95% CI: 0.26-1.66; p = 0.38), but higher for FA, which was 3.5%. The same happened with the need for transfusion (19.3% vs. 21.7%; OR: 1.07; 95% CI: 0.49-2.33; p = 0.87) compared with FA (7.1%).

Read also: EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation.

Vascular complications, intensive care stay, and survival were similar between non-transfemoral accesses.

Discharge directly to home without stroke or TIA was superior in the TC group compared with the AX group (87.8% vs. 62.3%; OR: 5.19; 95% CI: 2.45-11.0; p < 0.001). In the FA group, it was 90.3%.

Conclusion

Patients who underwent TAVR by transcaval access had a lower stroke rate, but a similar bleeding rate, compared with those who underwent TAVR by transaxillary access in this analysis from 8 sites in the United States. Both accesses present more complications than transfemoral access. Transcaval access may offer an attractive alternative.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Transcaval Versus Transaxillary TAVR in Contemporary Practice A Propensity-Weighted Analysis.

Reference: Robert J. Lederman J Am Coll Cardiol Intv 2022;15:965–975.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...